Abstract
Malaria diagnostic testing in high transmission settings remains a burden on healthcare systems. Here we present Remoscope, a portable automated imaging cytometer that scans fresh, unstained whole blood using a custom neural network on low-cost hardware. By screening up to two million red blood cells, Remoscope performs label-free quantitative stage-specific detection of Plasmodium falciparum (Pf) in 1-12 minutes without sample fixation, staining, or slide scanning. Flow is used to achieve high cellular throughput, with blood confined to a 4.5 µm monolayer in low-cost disposable flow cartridges. Remoscope performance was benchmarked in vitro by titration of cultured parasites into uninfected whole blood at concentrations of 17.1-710,000 parasites/µL. Counts generated by Remoscope demonstrated a linear response across the entire range. Considering drug susceptibility assays, the half-maximal effective concentration (EC50) of chloroquine (CQ) for the W2 strain of Pf was 211 nM by Remoscope, compared to 191 nM for conventional flow cytometry. Remoscope’s real-world diagnostic accuracy was evaluated in a cohort of 500 individuals in eastern Uganda, comprising 601 unique clinic visits. Parallel measurements of parasitemia were performed using Remoscope, qPCR targeting the multicopy conserved var gene acidic terminal sequence, and microscopic evaluation of Giemsa-stained thick blood smears. Remoscope’s limit of detection with respect to qPCR was 95.1 parasites/µL. At this threshold, the system had a sensitivity of 83%, specificity of 96%, Positive Predictive Value (PPV) of 91%, and a Negative Predictive Value (NPV) of 93%. Remoscope’s speed, accuracy, low cost, and ease of use address practical challenges in malaria diagnostic settings around the world. As a general imaging flow cytometer, Remoscope may also inform the development of recognition models for the diagnosis of other infectious and noninfectious blood disorders.
Competing Interest Statement
PML, RGS, and JLD declare international patent application No. PCT/US2021/047974.
Funding Statement
This work was funded by the Chan Zuckerberg Biohub San Francisco.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of California San Francisco gave ethical approval for this work. Ethics committee of Makerere University School of Medicine Research gave ethical approval for this work. Ethics commettee of the London School of Hygiene & Tropical Medicine gave ethical approval for this work. The University of California, San Francisco Committee on Human Research gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All data supporting the findings of this study will be made freely available before publication of the final version of this manuscript.
